Aravive (ARAV) Stock Price, News & Analysis

Company Overview

Aravive, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for cancers and other serious diseases. Its research centered on the GAS6/AXL signaling pathway, which is associated with tumor growth, metastasis, treatment resistance and immune-system evasion.

The company’s leading product candidate was batiraxcept, also known as AVB-500. Batiraxcept was an engineered soluble form of the AXL receptor designed to bind the GAS6 ligand and inhibit signaling. Aravive evaluated the candidate in clinical studies for advanced solid tumors, including platinum-resistant ovarian cancer and renal cell carcinoma.

Aravive conducted its development activities primarily through clinical programs in the United States and worked with academic and industry research partners. Gail McIntyre, Ph.D., MBA, served as the company’s chief executive officer during its later development period. After a Phase 3 study of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint in 2023, Aravive announced plans to discontinue operations and pursue the orderly wind-down of the business.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.04 to $0.04
• 52-Week Range: $0.04 to $2.46
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 10/27/2021
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARAV
• CIK: 1513818
• Web: www.aravive.com
• Phone: (936) 355-1910
• Fax: N/A
• Employees: 20
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: No Data
• Beta: N/A